The Peptide Knowledge Center

FDA-approved PTHrP analog for osteoporosis in high-risk patients.

Investigational HGH fragment studied for fat metabolism.

Erythropoietin-derived peptide studied for tissue protection and neuropathic pain.

Investigational peptide studied for tissue healing and gastrointestinal protection.

Long-acting amylin analog studied for weight management, often paired with semaglutide (CagriSema).

FDA-approved 32-amino-acid peptide for bone conditions.

FDA-approved GnRH antagonist used in assisted reproduction.

Long-acting growth hormone-releasing hormone (GHRH) analog under investigation.

Research blend combining GHRH analog with GHRP-6.

Popular research blend combining a GHRH analog with a selective GH secretagogue.

FDA-approved adrenocorticotropic hormone preparation.

FDA-approved GnRH antagonist for advanced prostate cancer.

FDA-approved synthetic vasopressin analog.

Angiotensin IV analog studied for cognitive enhancement and synaptogenesis.

Nonapeptide investigated for sleep, stress, and analgesic effects.

FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes.

FDA-approved HIV fusion inhibitor peptide.

Investigational tetrapeptide studied for telomere and aging biology.

FDA-approved GLP-1 receptor agonist for type 2 diabetes.

Recombinant follistatin isoform studied as a myostatin inhibitor.

Investigational copper-binding tripeptide studied for skin and hair.

Growth hormone-releasing peptide studied as GH secretagogue.

Ghrelin mimetic studied for GH release and appetite.

Dermal-focused research bundle grouping three skin-signaling peptides.

Research dermal blend combining skin- and repair-focused peptides.

FDA-approved peptide hormone used to treat severe hypoglycemia.

FDA-approved synthetic GnRH used diagnostically.

FDA-approved GnRH agonist implant.

Potent ghrelin mimetic studied for GH release and cardiac effects.

FDA-approved glycopeptide hormone used for fertility and hypogonadism.

Mitochondrial-derived peptide studied for cytoprotection and metabolic effects.

FDA-approved bradykinin B2 antagonist for hereditary angioedema attacks.

Long-acting IGF-1 analog used in research settings.

Immune-focused research bundle.

FDA-approved peptide hormone essential for glucose regulation.

Selective ghrelin receptor agonist studied for growth hormone release.

GH-axis plus tissue-repair research bundle.

Investigational reproductive-axis peptide.

Premium research blend combining anti-inflammatory and repair peptides.

Premium repair and skin-signaling bundle.

C-terminal tripeptide fragment of α-MSH studied for anti-inflammatory effects.

Endogenous tripeptide antioxidant studied for oxidative stress and skin research.

FDA-approved long-acting somatostatin analog.

FDA-approved GnRH agonist for prostate cancer, endometriosis, and central precocious puberty.

FDA-approved guanylate cyclase-C agonist for IBS-C and CIC.

FDA-approved daily GLP-1 receptor agonist for diabetes and obesity.

Investigational melanocortin agonist studied for pigmentation and sexual response.

Synthetic α-MSH analog approved for erythropoietic protoporphyria (EPP).

Investigational mitochondrial-derived peptide studied for metabolism.

Mitochondrial-support research bundle.

Coenzyme central to cellular energy metabolism, studied for aging and metabolic research.

Cognitive and neuroprotective research bundle.

FDA-approved somatostatin analog for endocrine tumors and acromegaly.

FDA-approved peptide hormone used in obstetrics.

Small peptide derived from CNTF studied for neurogenesis.

Peptide analog of spadin studied as a rapid-acting antidepressant candidate.

Short bioregulator tripeptide studied for cognitive and neuroprotective effects.

FDA-approved uroguanylin analog for constipation disorders.

FDA-approved synthetic amylin analog used with insulin in diabetes.

Immune plus mitochondrial research bundle.

Khavinson-family peptide studied for prostate tissue support.

FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women.

GH-axis pulse research bundle.

Tissue-repair plus anti-inflammatory research bundle.

Investigational triple GIP/GLP-1/glucagon receptor agonist.

Investigational anxiolytic peptide developed in Russia.

FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management.

Investigational nootropic peptide developed in Russia.

GHRH(1-29) fragment historically approved for pediatric growth hormone deficiency.

FDA-approved MC4R agonist for rare genetic obesity.

Investigational mitochondrial-targeted peptide for mitochondrial disease.

Synthetic fragment of thymosin beta-4 studied for tissue repair and inflammation.

FDA-approved GLP-2 analog for short bowel syndrome.

FDA-approved PTH(1-34) analog for osteoporosis.

FDA-approved GHRH analog for HIV-associated lipodystrophy.

Combines FDA-approved tesamorelin with selective GH secretagogue ipamorelin.

Khavinson-family peptide studied for immune and thymic function.

Immunomodulatory peptide approved abroad; not FDA-approved in the U.S.

Investigational actin-binding peptide studied for tissue repair.

FDA-approved dual GIP/GLP-1 receptor agonist for diabetes and obesity.

FDA-approved antidiuretic peptide used for vasodilatory shock.

Vascular bioregulator tripeptide studied for endothelial support.

Immune bioregulator dipeptide studied for thymus and immune modulation.

Classic research blend pairing BPC-157 with TB-500.

Repair-focused research bundle.